# Clinical Trial: High Doses of CBD Superior to Placebo in Treating Neuropathic Pain > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/clinical-trial-high-doses-of-cbd-superior-to-placebo-in-treating-neuropathic-pain/ > **Published:** 2026-06-19T17:33:30-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:51:25-04:00 > **Clinical Summary:** High-dose CBD shows efficacy vs. placebo in neuropathic pain. Clinical guidance on dosing, patient selection, and monitoring. --- ✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CBDPainResearchNeurologyDosingSafetyPolicy Why This Matters This trial provides clinicians with evidence-based dosing data for cannabidiol in [neuropathic pain](https://cedclinic.com/cannabis-for-pain-relief/) management, potentially offering an alternative for patients who fail or cannot tolerate conventional analgesics like gabapentin or pregabalin. Clinicians can now reference published efficacy data when counseling patients about CBD’s benefits and limitations, improving informed decision-making in their [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) strategies. The identification of effective high-dose CBD protocols enables more standardized prescribing practices rather than the current reliance on anecdotal dosing. Clinical Summary A randomized controlled trial published in eClinical Medicine demonstrated that high-dose cannabidiol (CBD) was superior to placebo in reducing [neuropathic pain](https://cedclinic.com/cannabis-for-pain-relief/) symptoms, suggesting potential therapeutic value for patients with this difficult-to-treat condition. The study findings indicate that CBD may offer an alternative or adjunctive option for neuropathic [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/), particularly for patients who have inadequate response to or intolerance of conventional analgesics. Given the prevalence of [neuropathic pain](https://cedclinic.com/cannabis-for-pain-relief/) in [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) and the limitations of existing pharmacotherapies, these results provide evidence-based support for considering CBD in appropriate patient populations. However, clinicians should note that optimal dosing regimens, long-term safety data, and comparative effectiveness relative to standard treatments still require further investigation. The practical takeaway for clinicians is that high-dose CBD now has clinical trial support for neuropathic pain, warranting consideration in discussions with eligible patients while awaiting additional evidence on dosing, duration, and long-term outcomes. Dr. Caplan’s Take “This randomized controlled trial adds meaningful evidence to our understanding of CBD’s role in neuropathic [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/), though we’ll want to see these findings replicated across different patient populations and dosing protocols before making it a standard recommendation in my practice.” Clinical Perspective 💊 This randomized controlled trial adds to the growing body of evidence that cannabidiol may have analgesic properties for neuropathic pain, a condition notoriously difficult to treat with conventional medications. However, clinicians should interpret these findings with appropriate caution, as neuropathic pain populations are heterogeneous, trial duration and sample sizes often remain modest, and the optimal dosing, patient selection criteria, and long-term safety profile of high-dose CBD require further clarification. The lack of [FDA approval](https://cedclinic.com/medicare-cannabis-reimbursement-policy-fda-approval/) for cannabis-derived cannabinoids for pain management means prescribing remains outside standard pharmaceutical pathways in most jurisdictions, creating documentation and liability considerations for practitioners. When patients with refractory neuropathic pain inquire about CBD, a reasonable clinical approach is to acknowledge the emerging evidence while discussing the current regulatory landscape, quality and purity concerns in unregulated products, and the importance of monitoring for drug interactions and [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) if patients 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Clinical%20Trial%3A%20High%20Doses%20of%20CBD%20Superior%20to%20Placebo%20in%20Treating%20Neuropathic%20Pain%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59772)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59772)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Clinical%20Trial%3A%20High%20Doses%20of%20CBD%20Superior%20to%20Placebo%20in%20Treating%20Neuropathic%20Pain%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59772)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Cannabis, Inflammation, and Anxiety: What the Research Shows](https://cedclinic.com/cannabis-inflammation-anxiety-sleep/) - [Lighting Up to Chill Out: A Field Guide to Anxiety and the Almighty Exhale – Folio Weekly](https://cedclinic.com/cannabis-effects-on-anxiety-clinical-insights/) - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://norml.org/news/2026/06/18/clinical-trial-high-doses-of-cbd-superior-to-placebo-in-treating-neuropathic-pain/?amp](https://norml.org/news/2026/06/18/clinical-trial-high-doses-of-cbd-superior-to-placebo-in-treating-neuropathic-pain/?amp) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).